EDITORIAL
Published on 20 Dec 2022
Editorial: Engineered immune cells in cancer immunotherapy (EICCI)
doi 10.3389/fimmu.2022.1119363
- 1,304 views
- 1 citation
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Engineered Immune Cells in Cancer Immunotherapy (EICCI)
Engineered Immune Cells in Cancer Immunotherapy (EICCI)
175k
Total downloads
629k
Total views and downloads
Articles
ORIGINAL RESEARCH
Published on 22 Jul 2022
Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation
doi 10.3389/fimmu.2022.864868
- 4,218 views
- 14 citations
REVIEW
Published on 11 May 2022
Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?
doi 10.3389/fimmu.2022.795164
- 13,087 views
- 46 citations
ORIGINAL RESEARCH
Published on 22 Apr 2022
Human Tumor Targeted Cytotoxic Mast Cells for Cancer Immunotherapy
doi 10.3389/fonc.2022.871390
- 4,721 views
- 20 citations
REVIEW
Published on 31 Mar 2022
Harnessing the Anti-Tumor Mediators in Mast Cells as a New Strategy for Adoptive Cell Transfer for Cancer
doi 10.3389/fonc.2022.830199
- 2,795 views
- 10 citations
ORIGINAL RESEARCH
Published on 30 Mar 2022
Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021
doi 10.3389/fimmu.2022.822004
- 3,798 views
- 17 citations
ORIGINAL RESEARCH
Published on 18 Mar 2022
A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021
doi 10.3389/fimmu.2022.840956
- 11,719 views
- 53 citations
REVIEW
Published on 28 Oct 2021
Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward
doi 10.3389/fimmu.2021.765097
- 9,450 views
- 27 citations
ORIGINAL RESEARCH
Published on 12 Aug 2021
PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies
doi 10.3389/fimmu.2021.665970
- 8,697 views
- 37 citations
CASE REPORT
Published on 25 May 2021
PiggyBac-Generated CAR19-T Cells Plus Lenalidomide Cause Durable Complete Remission of Triple-Hit Refractory/Relapsed DLBCL: A Case Report
doi 10.3389/fimmu.2021.599493
- 4,739 views
- 12 citations
CASE REPORT
Published on 07 May 2021
Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma
doi 10.3389/fonc.2021.669071
- 8,261 views
- 54 citations
REVIEW
Published on 03 May 2021
Naturally Occurring Genetic Alterations in Proximal TCR Signaling and Implications for Cancer Immunotherapy
doi 10.3389/fimmu.2021.658611
- 5,832 views
- 6 citations
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore